

Date of preparation: 3 June 2024

Issuer's abbreviated name: SYNEKTIK SA

Current report: 29/2024 ESPI

Subject: Information on the conclusion of a significant sales agreement

Legal basis: Article 17(1) of the Market Abuse Regulation – inside information

Body of the report:

Time of publication: 7:50 a.m.

The Management Board of Synektik SA (Company) reports that the Company has learned that its subsidiary doing business as SYNEKTIK Czech Republic, s.r.o. with its registered office in Prague, Czech Republic, concluded a significant agreement with the Hospital in Pardubice (Nemocnice Pardubického kraje, a.s.) with its registered office at Kyjevská 44, 532 03 Pardubice, Czech Republic (Hospital).

The agreement pertains to on-going supplies of instruments and accessories to be used by the Hospital's da Vinci minimally invasive surgery robotic system.

This agreement was concluded as a result of the procedure conducted in accordance with Czech public procurement law, and its maximum net value is CZK 88 132 400,00.

The signing of this agreement has been deemed to be significant by the Management Board of Synektik SA since its maximum net value exceeds 5% of the equity of the Synektik Group disclosed in the last periodic report, meaning that it surpasses the level prescribed internally in the Company in its individual reporting standards. The proceeds generated by executing this project will affect the sales results in the 2023 financial year lasting from 1 October 2023 to 30 September 2024, as well as in subsequent financial years from 2024 to 2027.



Persons representing the Issuer:

Cezary Kozanecki – President of the
Management Board